Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Covigenix VAX-001
- Development stage
- Phase 2
- Lead developer
- Entos Pharmaceuticals
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Covigenix VAX-001 is a novel plasmid DNA-based vaccine developed to prevent COVID-19. It encodes the full-length Spike (S) protein of SARS-CoV-2 and is delivered using a proprietary Fusogenix proteo-lipid vehicle (PLV) platform. This technology enables efficient delivery of the DNA into cells, where it stimulates both humoral and cell-mediated immune responses against the virus. The vaccine has demonstrated safety and immunogenicity in preclinical studies and early-phase clinical trials. It offers advantages such as stability at room temperature for one month and at 4–8°C for up to one year, simplifying storage and distribution logistics[1][5][7].
- Brand names
- Covigenix VAX-001
- Other names
- COVID-19 DNA vaccine - Entos PharmaceuticalsCOVID19 DNA vaccine - Entos PharmaceuticalsCOVID 19 DNA vaccine - Entos PharmaceuticalsSARS-CoV-2 vaccine - Entos PharmaceuticalsSARS-CoV2 vaccine - Entos PharmaceuticalsSARS-CoV 2 vaccine - Entos Pharmaceuticals
02
Targets
SARS-CoV-2 spikeACE2 (Angiotensin-converting enzyme 2)
Beyond the preview
Go deeper on Covigenix VAX-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Covigenix VAX-001.